Clinical Trial Update: A Double-blind Study to Compare the Efficacy, Safety, and Immunogenicity of the Proposed Biosimilar Ustekinumab FYB202 to Stelara® in Patients With Moderate-to-Severe Plaque Psoriasis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating a proposed biosimilar ustekinumab (FYB202) versus Stelara in moderate-to-severe plaque psoriasis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• FYB202 (biosimilar ustekinumab) (ustekinumab)
• Stelara (ustekinumab)

Snippet

Sponsor: Bioeq GmbH | Conditions: Plaque Psoriasis | Phase 3 | Status: COMPLETED